FEATURED COMPANIES
- Amgen Inc.
- AstraZeneca Plc
- Bayer AG
- F. Hoffmann-La Roche Ltd.
- Pfizer Inc.
- MORE
1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
Global Chronic Renal Failure Therapeutics Market: About this market
Chronic renal failure is a general term for a set of heterogeneous disorders that affect the structure and function of the kidney. The chronic renal failure therapeutics market analysis considers sales of antihypertensive therapeutics, antianemia therapeutics, and others. Our analysis also considers the sales of chronic renal failure therapeutics in Asia, Europe, North America, and ROW. In 2018, the antihypertensive therapeutics segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the inclusion of antihypertensive therapeutics into various reimbursement schemes will play a significant role in the antihypertensive therapeutics segment to maintain its market position. Also, our global chronic renal failure therapeutics market report looks at factors such as the rising prevalence of chronic renal failure, a strong pipeline and recent approvals, and initiatives from government agencies. However, high genericization of the market, lack of disease-modifying agents, and late diagnosis of polypharmacy may hamper the growth of the chronic renal failure therapeutics industry over the forecast period.
Global Chronic Renal Failure Therapeutics Market: Overview
Rising prevalence of chronic renal failure
The rise in the number of people suffering from cardiovascular and metabolic disorders can result in an increased prevalence of chronic renal failure. There is a high concentration of patients with chronic renal failure from the US, Europe, and Asia. This will boost the need for chronic renal failure therapeutics in these countries and lead to the expansion of the global chronic renal failure therapeutics market at a CAGR of almost 5% during the forecast period.
Development of novel hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors
It has been observed that the oral administration of HIF-PH drugs is ideal for patients. Also, oral HIF-PH inhibitors exhibit minimal side-effects in comparison to other therapeutics. The penetration of these drugs across healthcare centers of various countries is expected to have a positive impact on the overall market growth.
Competitive Landscape
With the presence of several major players, the global chronic renal failure therapeutics market is fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading chronic renal failure therapeutics manufacturers, that include Amgen Inc., AstraZeneca Plc, Bayer AG, F. Hoffmann-La Roche Ltd., and Pfizer Inc.
Also, the chronic renal failure therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Chronic renal failure is a general term for a set of heterogeneous disorders that affect the structure and function of the kidney. The chronic renal failure therapeutics market analysis considers sales of antihypertensive therapeutics, antianemia therapeutics, and others. Our analysis also considers the sales of chronic renal failure therapeutics in Asia, Europe, North America, and ROW. In 2018, the antihypertensive therapeutics segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the inclusion of antihypertensive therapeutics into various reimbursement schemes will play a significant role in the antihypertensive therapeutics segment to maintain its market position. Also, our global chronic renal failure therapeutics market report looks at factors such as the rising prevalence of chronic renal failure, a strong pipeline and recent approvals, and initiatives from government agencies. However, high genericization of the market, lack of disease-modifying agents, and late diagnosis of polypharmacy may hamper the growth of the chronic renal failure therapeutics industry over the forecast period.
Global Chronic Renal Failure Therapeutics Market: Overview
Rising prevalence of chronic renal failure
The rise in the number of people suffering from cardiovascular and metabolic disorders can result in an increased prevalence of chronic renal failure. There is a high concentration of patients with chronic renal failure from the US, Europe, and Asia. This will boost the need for chronic renal failure therapeutics in these countries and lead to the expansion of the global chronic renal failure therapeutics market at a CAGR of almost 5% during the forecast period.
Development of novel hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors
It has been observed that the oral administration of HIF-PH drugs is ideal for patients. Also, oral HIF-PH inhibitors exhibit minimal side-effects in comparison to other therapeutics. The penetration of these drugs across healthcare centers of various countries is expected to have a positive impact on the overall market growth.
Competitive Landscape
With the presence of several major players, the global chronic renal failure therapeutics market is fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading chronic renal failure therapeutics manufacturers, that include Amgen Inc., AstraZeneca Plc, Bayer AG, F. Hoffmann-La Roche Ltd., and Pfizer Inc.
Also, the chronic renal failure therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Amgen Inc.
- AstraZeneca Plc
- Bayer AG
- F. Hoffmann-La Roche Ltd.
- Pfizer Inc.
- MORE
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 08: GEOGRAPHIC LANDSCAPE
PART 10: DRIVERS AND CHALLENGES
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Product - Market share 2018-2023 (%)
Exhibit 18: Comparison of product
Exhibit 19: Antihypertensive therapeutics - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Antihypertensive therapeutics - Year-over-year growth 2019-2023 (%)
Exhibit 21: Antianemia therapeutics - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Antianemia therapeutics - Year-over-year growth 2019-2023 (%)
Exhibit 23: Others - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Others - Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by product
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 33: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 35: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 37: Key leading countries
Exhibit 38: Market opportunity
Exhibit 39: Late Stage Molecules for the treatment of chronic renal failure
Exhibit 40: Impact of drivers and challenges
Exhibit 41: HIF-PH inhibitors under Phase III development
Exhibit 42: Strategic alliances
Exhibit 43: Vendor landscape
Exhibit 44: Landscape disruption
Exhibit 45: Vendors covered
Exhibit 46: Vendor classification
Exhibit 47: Market positioning of vendors
Exhibit 48: Amgen Inc. - Vendor overview
Exhibit 49: Amgen Inc. - Business segments
Exhibit 50: Amgen Inc. - Organizational developments
Exhibit 51: Amgen Inc. - Geographic focus
Exhibit 52: Amgen Inc. - Key offerings
Exhibit 53: AstraZeneca Plc - Vendor overview
Exhibit 54: AstraZeneca Plc - Business segments
Exhibit 55: AstraZeneca Plc - Organizational developments
Exhibit 56: AstraZeneca Plc - Geographic focus
Exhibit 57: AstraZeneca Plc - Key offerings
Exhibit 58: Bayer AG - Vendor overview
Exhibit 59: Bayer AG - Business segments
Exhibit 60: Bayer AG - Organizational developments
Exhibit 61: Bayer AG - Geographic focus
Exhibit 62: Bayer AG - Segment focus
Exhibit 63: Bayer AG - Key offerings
Exhibit 64: F. Hoffmann-La Roche Ltd. - Vendor overview
Exhibit 65: F. Hoffmann-La Roche Ltd. - Business segments
Exhibit 66: F. Hoffmann-La Roche Ltd. - Organizational developments
Exhibit 67: F. Hoffmann-La Roche Ltd. - Geographic focus
Exhibit 68: F. Hoffmann-La Roche Ltd. - Segment focus
Exhibit 69: F. Hoffmann-La Roche Ltd. - Key offerings
Exhibit 70: Pfizer Inc. - Vendor overview
Exhibit 71: Pfizer Inc. - Business segments
Exhibit 72: Pfizer Inc. - Organizational developments
Exhibit 73: Pfizer Inc. - Geographic focus
Exhibit 74: Pfizer Inc. - Segment focus
Exhibit 75: Pfizer Inc. - Key offerings
Exhibit 76: Validation techniques employed for market sizing
Exhibit 77: Definition of market positioning of vendors
PART 02: SCOPE OF THE REPORT
- Preface
- Currency conversion rates for US$
- Market ecosystem
- Market characteristics
- Market segmentation analysis
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
- Market segmentation by product
- Comparison by product
- Antihypertensive therapeutics - Market size and forecast 2018-2023
- Antianemia therapeutics - Market size and forecast 2018-2023
- Others - Market size and forecast 2018-2023
- Market opportunity by product
PART 08: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2018-2023
- Europe - Market size and forecast 2018-2023
- Asia - Market size and forecast 2018-2023
- ROW - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 10: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
- Development of novel hypoxia-inducible factor prolyl hydroxylase
- (HIF-PH) inhibitors
- Exploring research toward precision medicine
- Strategic alliances
- Overview
- Landscape disruption
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Amgen Inc.
- AstraZeneca Plc
- Bayer AG
- F. Hoffmann-La Roche Ltd.
- Pfizer Inc.
- Research methodology
- List of abbreviations
- Definition of market positioning of vendors
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Product - Market share 2018-2023 (%)
Exhibit 18: Comparison of product
Exhibit 19: Antihypertensive therapeutics - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Antihypertensive therapeutics - Year-over-year growth 2019-2023 (%)
Exhibit 21: Antianemia therapeutics - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Antianemia therapeutics - Year-over-year growth 2019-2023 (%)
Exhibit 23: Others - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Others - Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by product
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 33: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 35: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 37: Key leading countries
Exhibit 38: Market opportunity
Exhibit 39: Late Stage Molecules for the treatment of chronic renal failure
Exhibit 40: Impact of drivers and challenges
Exhibit 41: HIF-PH inhibitors under Phase III development
Exhibit 42: Strategic alliances
Exhibit 43: Vendor landscape
Exhibit 44: Landscape disruption
Exhibit 45: Vendors covered
Exhibit 46: Vendor classification
Exhibit 47: Market positioning of vendors
Exhibit 48: Amgen Inc. - Vendor overview
Exhibit 49: Amgen Inc. - Business segments
Exhibit 50: Amgen Inc. - Organizational developments
Exhibit 51: Amgen Inc. - Geographic focus
Exhibit 52: Amgen Inc. - Key offerings
Exhibit 53: AstraZeneca Plc - Vendor overview
Exhibit 54: AstraZeneca Plc - Business segments
Exhibit 55: AstraZeneca Plc - Organizational developments
Exhibit 56: AstraZeneca Plc - Geographic focus
Exhibit 57: AstraZeneca Plc - Key offerings
Exhibit 58: Bayer AG - Vendor overview
Exhibit 59: Bayer AG - Business segments
Exhibit 60: Bayer AG - Organizational developments
Exhibit 61: Bayer AG - Geographic focus
Exhibit 62: Bayer AG - Segment focus
Exhibit 63: Bayer AG - Key offerings
Exhibit 64: F. Hoffmann-La Roche Ltd. - Vendor overview
Exhibit 65: F. Hoffmann-La Roche Ltd. - Business segments
Exhibit 66: F. Hoffmann-La Roche Ltd. - Organizational developments
Exhibit 67: F. Hoffmann-La Roche Ltd. - Geographic focus
Exhibit 68: F. Hoffmann-La Roche Ltd. - Segment focus
Exhibit 69: F. Hoffmann-La Roche Ltd. - Key offerings
Exhibit 70: Pfizer Inc. - Vendor overview
Exhibit 71: Pfizer Inc. - Business segments
Exhibit 72: Pfizer Inc. - Organizational developments
Exhibit 73: Pfizer Inc. - Geographic focus
Exhibit 74: Pfizer Inc. - Segment focus
Exhibit 75: Pfizer Inc. - Key offerings
Exhibit 76: Validation techniques employed for market sizing
Exhibit 77: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Amgen Inc.
- AstraZeneca Plc
- Bayer AG
- F. Hoffmann-La Roche Ltd.
- Pfizer Inc.
- MORE
The following companies are recognised as the key players in the global chronic renal failure therapeutics market: Amgen Inc., AstraZeneca Plc, Bayer AG, F. Hoffmann-La Roche Ltd., and Pfizer Inc.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the development of novel hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors.”
According to the report, one of the major drivers for this market is the rising prevalence of chronic renal failure.
Further, the report states that one of the major factors hindering the growth of this market is the lack of disease-modifying agents.
The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the development of novel hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors.”
According to the report, one of the major drivers for this market is the rising prevalence of chronic renal failure.
Further, the report states that one of the major factors hindering the growth of this market is the lack of disease-modifying agents.
The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
- Amgen Inc.
- AstraZeneca Plc
- Bayer AG
- F. Hoffmann-La Roche Ltd.
- Pfizer Inc.
Note: Product cover images may vary from those shown
LOADING...
